These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25139841)

  • 1. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
    Liu L; Cao Y; Tan A; Liao C; Gao F
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
    Su X; Lacouture ME; Jia Y; Wu S
    Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rash conclusions from a phase 3 study of cetuximab?
    Harrington KJ
    Lancet Oncol; 2010 Jan; 11(1):2-3. PubMed ID: 20129123
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
    Zhang S; Chen J; Jiang H; Ma H; Yang B
    Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
    Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
    Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
    Maitland ML; Levine MR; Lacouture ME; Wroblewski KE; Chung CH; Gordon IO; Szeto L; Ratko G; Soltani K; Kozloff MF; Hoffman PC; Salgia R; Carbone DP; Karrison TG; Vokes EE
    BMC Cancer; 2014 Jan; 14():5. PubMed ID: 24386952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
    Liu HB; Wu Y; Lv TF; Yao YW; Xiao YY; Yuan DM; Song Y
    PLoS One; 2013; 8(1):e55128. PubMed ID: 23383079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17.
    Sommeijer DW; Karapetis CS; Zalcberg JR; Tu D; Jonker DJ; Simes J; Tebbutt N; Yip D; Price TJ; O'Callaghan CJ
    Acta Oncol; 2014 Jul; 53(7):877-84. PubMed ID: 24495042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
    Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
    J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.
    Petrelli F; Borgonovo K; Barni S
    Target Oncol; 2013 Sep; 8(3):173-181. PubMed ID: 23321777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
    Göksu SS; Tatlı AM; Geredeli Ç; Atcı M; Besen AA; Mertsoylu H; Uysal M; Özdoğan M; Aydın SG; Bilici A; Karaağaç M; Artaç M; Kaplan MA; Ebinç S; Coşkun HŞ
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):805-812. PubMed ID: 34312705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.
    Bahassi el M; Li YQ; Wise-Draper TM; Deng L; Wang J; Darnell CN; Wilson KM; Wells SI; Stambrook PJ; Rixe O
    Eur J Cancer; 2013 Jul; 49(10):2345-55. PubMed ID: 23578570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
    Funakoshi T; Suzuki M; Tamura K
    Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
    Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
    Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.